Phase 3 Recruiting Network
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…
Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Sites in Pennsylvania: - Jefferson Abington Hospital — Abington, Pennsylvania
- Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
- Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
- Geisinger Medical Center — Danville, Pennsylvania
- Penn State Children's Hospital — Hershey, Pennsylvania
Phase 3 Recruiting Network
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with alkylating agents. Alkylating agents are part of s…
Sponsor: Children's Oncology Group
NCT ID: NCT06513962
Sites in Pennsylvania: - Christiana Care Health System-Concord Health Center — Chadds Ford, Pennsylvania
- Penn State Children's Hospital — Hershey, Pennsylvania
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- Saint Christopher's Hospital for Children — Philadelphia, Pennsylvania
- Children's Hospital of Pittsburgh of UPMC — Pittsburgh, Pennsylvania
Phase 3 Recruiting Network
Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy given per standard institutional guidelines +/- bevacizumab on Day 1 every 21 days for 3-4 cycles. Registered patients who progress during neoadj…
Sponsor: GOG Foundation
NCT ID: NCT05659381
Sites in Pennsylvania: - Jefferson Abington Hospital — Abington, Pennsylvania
- Jefferson Hospital — Jefferson Hills, Pennsylvania
- Forbes Hospital — Monroeville, Pennsylvania
- West Penn Hospital — Pittsburgh, Pennsylvania
- Wexford Hospital — Wexford, Pennsylvania
Phase 3 Recruiting Industry
The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.
Sponsor: Incyte Corporation
NCT ID: NCT07214779
Sites in Pennsylvania: - University of Pittsburgh Cancer Institute Cancer Services — Pittsburgh, Pennsylvania
- Allegheny Health Network- West Penn Hospital — Pittsburgh, Pennsylvania
- Lankenau Medical Center — Wynnewood, Pennsylvania
- Wellspan Gynecologic Oncology — York, Pennsylvania
Phase 2, Phase 3 Recruiting Industry
This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.
Sponsor: Daiichi Sankyo
NCT ID: NCT06161025
Sites in Pennsylvania: - Perelman School of Medicine at the University of Pennsylvania — Philadelphia, Pennsylvania
Phase 3 Recruiting Industry
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Sponsor: Verastem, Inc.
NCT ID: NCT06072781
Sites in Pennsylvania: - Asplundh Cancer Pavilion | Jefferson Health — Philadelphia, Pennsylvania
- Allegheny Health Network — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer get…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06824467
Sites in Pennsylvania: - Allegheny Health Network West Penn Hospital ( Site 0099) — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice…
Sponsor: Genelux Corporation
NCT ID: NCT05281471
Sites in Pennsylvania: - AHN West Penn Hospital — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expr…
Sponsor: Daiichi Sankyo
NCT ID: NCT06819007
Sites in Pennsylvania: - St. Lukes University Health Network — Bethlehem, Pennsylvania
- Ann B Barshinger Cancer Institute — Lancaster, Pennsylvania
Phase 3 Recruiting Academic/Other
This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT04575935
Sites in Pennsylvania: - St. Luke's University Health Network — Bethlehem, Pennsylvania
Phase 3 Recruiting Industry
This Phase 3 study is designed to investigate the safety, diagnostic performance, and clinical usefulness of Gleolan for the real-time detection and visualization of epithelial ovarian cancer tumors during debulking surgery. The study is p…
Sponsor: NX Development Corp
NCT ID: NCT05804370
Sites in Pennsylvania: - WellSpan Health — York, Pennsylvania
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Pennsylvania: - Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
- UPMC Altoona — Altoona, Pennsylvania
- Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
- Bryn Mawr Hospital — Bryn Mawr, Pennsylvania
- Pocono Medical Center — East Stroudsburg, Pennsylvania
Phase 2 Recruiting Industry
This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conduct…
Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCT ID: NCT05128825
Sites in Pennsylvania: - Site 0232 - University of Pennsylvania — Philadelphia, Pennsylvania
- Site 0178 - Thomas Jefferson University — Philadelphia, Pennsylvania
- Site 0277 - Alliance Cancer Specialist, PC — Wynnewood, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Pennsylvania: - University of Pennsylvania / Abramson Cancer Center — Philadelphia, Pennsylvania
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in Pennsylvania: - USOR Alliance Cancer Specialist — Doylestown, Pennsylvania
- Allegheny Health Network — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Pennsylvania: - Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
- WellSpan York Cancer Center — York, Pennsylvania
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in Pennsylvania: - Thomas Jefferson University — Philadelphia, Pennsylvania
Phase 2 Recruiting Industry
Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine …
Sponsor: AbbVie
NCT ID: NCT07059845
Sites in Pennsylvania: - Penn Medicine University of Pennsylvania Health System /ID# 277963 — Philadelphia, Pennsylvania
- Western Pennsylvania Gynecologic Oncology /ID# 278632 — Pittsburgh, Pennsylvania
Phase 2 Recruiting Industry
A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.
Sponsor: TORL Biotherapeutics, LLC
NCT ID: NCT06690775
Sites in Pennsylvania: - SCRI - Alliance Cancer Specialists, PC — Doylestown, Pennsylvania
- University of Pennsylvania — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Pennsylvania: - Allegheny Health Network — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in comb…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT04104776
Sites in Pennsylvania: - Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Pennsylvania: - Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- Children's Hospital of Pittsburgh of UPMC — Pittsburgh, Pennsylvania
Phase 2 Recruiting Industry
This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on participants who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective th…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06787612
Sites in Pennsylvania: - University of Pittsburgh Medical Center, Magee-Womens Hospital — Pittsburgh, Pennsylvania
- West Penn Hospital of Allegheny Health Network — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
The purpose of this multicenter, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in participants with ovarian cancer and Non…
Sponsor: Tubulis GmbH
NCT ID: NCT06303505
Sites in Pennsylvania: - Allegheny Singer — Pittsburgh, Pennsylvania
Phase 2 Recruiting Industry
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
Sponsor: Faeth Therapeutics
NCT ID: NCT06463028
Sites in Pennsylvania: - Alliance Cancer Specialists, PC — Doylestown, Pennsylvania
- West Penn Hospital — Pittsburgh, Pennsylvania